GH1 and cancer: The pleiotropic antagonism of growth hormone (GH) and its major downstream effector, insulin-like growth factor 1 (IGF1), in driving proliferative and invasive growth of multiple different types of cancer, especially at the paracrine/autocrine level and with increasing age, has now established it as a serious anti-cancer strategy (1–3).